Arformoterol Tartrate
FDA Approved: * November 9, 2021Pharm Company: * TEVA PHARMS USA
Category: Lungs (Pulmonary)
Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1] It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006, for the treatment o... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Related Brands
Drugs with the same active ingredientsPopular Topics
I started taking Metoprolol Tart 25mg prescribed by the ER..Ever since i started taking it my vision has gotten really b...
2 REPLIEScan I take zolpidem with augmentin 875-125 ## I didn't find any interactions listed between these two medications, b...
4 REPLIESI take half of a 10 mg of Zolpidem to help me sleep. Lately I have been experiencing crawling and itching of the skin. I...
3 REPLIESgeneric-for heart & blood pressure ## i have been taking metroprol 50 mg for 3-4 months and am experiencing in the m...
3 REPLIESround, purple, M Z1, tablet ## has anyone seen a zolpidem {or any meds} that are small round purple pill w/M Z1 on one s...
2 REPLIESwhite oblong pill and onone side it say w517 the other side is blank.ii jst took andthis is to hlep ne seep ## Is it pos...
2 REPLIESSN 10 on one side of as white oblong scored pill ## Just to confirm, the pill in description is identified as Stilnox, a...
2 REPLIESOval shaped Apo on one side white 10 on other side new prescription oblong shaped peach-yellow 5 dots (like #5 dice) and...
2 REPLIESI know exactly what your taking about and they are fine. I suffer from chronic insomnia and could no longer afford to se...
1 REPLYSmall oval pill with APO on one side and ZOLS on the other ## The pill in description marked APO ZOL 5, is Zolpidem tart...
1 REPLY